A pharmacogenomics primer
A pharmacogenomics primer
复制标题
DOI：
10.1177/0091270007303768
复制
发表时间：
2007-09-01
影响因子：
2.9
通讯作者：
Court, Michael H.
中科院分区：
文献类型：
--
作者：
Court, Michael H.
人类基因组计划和相关的研究计划已经能够识别大量的遗传变异，这些变异可以预测药物反应和结果（药物基因组学生物标志物）。到目前为止，将常规药物基因组学检测纳入临床实践相对较少。采用的潜在障碍包括相对缺乏建立这种测试的好处的前瞻性对照试验，经济限制和伦理问题等。考虑在实践中使用药物基因组学检测的临床医生也可能不熟悉这一快速发展的学科的概念和原则。因此，本综述的目的是为临床药理学家提供一个关于药物基因组学原理和分子机制的基础。此外，还将描述目前用于发现新型药物基因组学生物标志物并将其应用于临床实践的方法。
The human genome project and related research initiatives have enabled the identification of a significant number of genetic variants that are predictive of drug response and outcome (pharmacogenomic biomarkers). As yet, incorporation of routine pharmacogenomic testing into clinical practice has been relatively modest. Potential barriers to adoption include a relative lack of prospective controlled trials establishing the benefits of such testing, economic constraints, and ethical concerns, among others. Clinicians considering the use of pharmacogenomic testing in their practice also may be unfamiliar with the concepts and principles underlying this rapidly evolving discipline. Consequently, the purpose of this review is to provide the clinical pharmacologist with a primer on the principles and molecular mechanisms underlying pharmacogenomics. In addition, the methods currently being used to discover novel pharmacogenomic biomarkers and then apply these to clinical practice will be described.